A patented 25-mg CBD drug developed by Ontario-based Maricann goes on sale in Germany next week.
Maricann CEO Ben Ward said the development “symbolizes a significant move to strengthen our global leadership position.”
The company says its patented system of drug delivery provides a “precise and consistent solid dosage.”
Mr. Ward said the new formulation is first of many that uses the company’s multi-patented VESIsorb(R) delivery system, designed “to ensure optimum absorption and bioavailability.”
The company claims that close to 200 million consumers in six continents have safely and effectively used a natural product formulated with VESIsorb(R) since 2007.
Jesse Lopez, CEO and founder of SourceOne Global Partners says that: ”Maricann has all of the critical elements to champion the VESIsorb(R) drug delivery system in the emerging global cannabis industry.”
“With a focus on innovation and clinical research, they also have the financial strength to build awareness and educate consumers on these superior product applications.”
Founded in 2013, Maricann is a producer and distributor of cannabis for medical purposes. Based in Ontario and Munich, Germany, it has production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada.
The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.